Compositions of transforming growth factor β(TGF-β) which promotes wound healing and methods for their use

Claim 2

A pharmaceutical composition, comprising: beta-transforming growth factor (TGF-β) having the following characteristics; (a) does not compete with epidermal growth factor (EGF) for receptor binding; (b) induces dose dependent formation of large colonies having a size of greater than 3,100 μm 2 of NRK 49F cells in a soft agar assay when activated by EGF or transforming growth factor-alpha (TGF-α) and (c) if not activated by EGF or transforming growth factor-alpha, does not induce NRK cells to form said large colonies in soft agar; and a pharmaceutically acceptable carrier therefor.

Claim 3

The composition of claim 1, which further comprises at least one activating agent selected from the group consisting of epidermal growth factor (EGF) and alpha-type transforming growth factor (TGF-α) present in an amount sufficient to activate said TGF-β.

Claim 4

A pharmaceutical composition, comprising: isolated and substantially homogeneous beta transforming growth factor (TGF-β) having the following characteristics: (a) acid stable; (b) an apparent molecular weight of about 25,000 to 26,000 daltons in the absence of a reducing agent as measured by SDS-PAGE; (c) an apparent molecular weight of about 12,500 daltons under reducing conditions as measured by SDS-PAGE; (d) does not compete with epidermal growth factor for receptor binding; (e) induces dose-dependent formation of large colonies having a size of greater than >3,100 μm 2 of NRK 49F cells in a soft agar assay when activated by epidermal growth factor (EGF) or transforming growth factor-alpha (TGF-α); being purified to the extent that (1) it does not induce NRK cells to form said large colonies in soft agar and (2) it produces a single band with an apparent molecular weight of about 12,500 daltons is shown on SDS-PAGE under reducing conditions and a single band with an apparent molecular weight of about 25,000 is shown under non-reducing conditions; and a pharmaceutically acceptable carrier therefor.

Claim 5

A pharmaceutical composition, comprising: isolated and substantially homogeneous beta transforming growth factor (TGF-β) having the following characteristics: (a) acid stable; (b) an apparent molecular weight of about 25,000 to 26,000 daltons in the absence of a reducing agent as measured by SDS-PAGE; (c) an apparent molecular weight of about 12,500 daltons under reducing conditions as measured by SDS-PAGE; (d) does not compete with epidermal growth factor for receptor binding; (e) induces dose-dependent formation of large colonies having a size of greater than >3,100 μm 2 of NRK 49F cells in a soft agar assay when activated by epidermal growth factor (EGF) or transforming growth factor-alpha (TGF-α); being purified to the extent that (1) it does not induce NRK cells to form said large colonies in soft agar and (2) it produces a single band with an apparent molecular weight of about 12,500 daltons is shown on SDS-PAGE under reducing conditions and a single band with an apparent molecular weight of about 25,000 is shown under non-reducing conditions; and a pharmaceutically acceptable carrier therefor.

Claim 6

The composition of claim 3, which is sterile.

Claim 7

The composition of claim 3, wherein said TGF-β is present in a concentration of at least about 1.0 ng/ml of said composition.

Claim 8

The composition of claim 3, wherein said TGF-β is present in a concentration of up to about 1.0 mg/ml of said composition.

Claim 9

The composition of claim 3, wherein said TGF-β is present in a concentration of at least about 1.0 ng/ml up to about 1.0 mg/ml of said composition.

Claim 10

The composition of claim 3, which is suitable for topical application.

Claim 11

The composition of claim 3, which further comprises at least one activating agent selected from the group consisting of epidermal growth factor (EGF) and alpha-type transforming growth factor (TGF-α) present in an amount sufficient to activate said TGF-β.

Claim 12

The composition of claim 9, wherein said activating agent is EGF.

Claim 13

The composition of claim 9, wherein said activating agent is TGF-α.

Claim 14

A method for promoting wound healing in mammals which comprises applying an effective amount of the composition of claim 3, to a mammal in need of such treatment.

Claim 15

The method of claim 12, wherein said composition is applied systemically.

Claim 16

The method of claim 12, wherein said composition is topically applied to a wound on said mammal in order to promote healing of said wound.

Claim 17

The method of claim 12, wherein said wound is a burn and wherein said composition is topically applied.

Claim 18

The method of claim 12, wherein said wound is an ulcer and wherein said composition is topically applied.

Claim 19

The method of claim 12, wherein said wound is a surgical incision and wherein the composition is topically applied.

Claim 20

The method of claim 12, wherein said mammal is a human.

Claim 21

A method for the treatment of skin wounds comprising: a) impregnating a dressing material with the composition of claim 1, and b) applying the thus impregnated dressing to wounded or traumatized skin.

Claim 22

A method for the treatment of skin wounds comprising: a) impregnating a dressing material with the composition of claim 2, and b) applying the thus impregnated dressing to wounded or traumatized skin.

Claim 23

A method of treating a mammalian topical wound, burn or ulcer comprising topically applying the pharmaceutical composition of claim 1 to said wound, burn or ulcer.

Claim 24

The method of claim 21, wherein said mammal is a human.

Claim 25

The method of claim 22, wherein said TGF-β is the sole active ingredient.

Claim 26

The method of claim 21, wherein said pharmaceutical composition further comprises alpha-type transforming growth factor or epidermal growth factor.

Claim 27

The method of claim 12, wherein said TGF-β is the sole active ingredient.

Claim 28

The pharmaceutical composition of claim 1, wherein said TGF-β is the sole active ingredient.

Claim 29

The pharmaceutical composition of claim 3, wherein said TGF-β is the sole active ingredient.